Indication: Prostate Cancer
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX:CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)
Sub-indication: Genitourinary Cancer
Study Type: Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Sponsor: Bristol-Myers Squibb (BMS)
Learn more at ClinicalTrials.gov
Email for more information: GU-NCIResearch@nortonhealthcare.org